Rita Nanda
Director, Breast Oncology Program · University of Chicago Medical Center
Credentials: · · ·
History
Research
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Journal of Clinical Oncology · 2016 · First of 12 authors · Corresponding · 1,239 citations
The molecular portraits of breast tumors are conserved across microarray platforms
BMC Genomics · 2006 · 1,043 citations
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Modern Pathology · 2006 · 818 citations
37 papers
34 papers
33 papers
31 papers · 6 as a fellow
29 papers
28 papers
- ML
28 papers
26 papers
Grants
- 2018–2022
UChicago Interdisciplinary Cancer Health Disparities SPORE
National Cancer Institute · P20
PI · $3.4M · University of Chicago
- 2010–2022
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
National Cancer Institute · U01
PI · $2.3M · University of Texas at Austin
Clinical trials
- 2026–2030
Principal investigator · Not yet recruiting
University of Chicago
- 2018–2025
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
Principal investigator · Terminated · Phase 2
University of Chicago
- 2017–2026
Principal investigator · Active not recruiting · Phase 2
University of Chicago
- 2016–2018
A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer
Principal investigator · Withdrawn
University of Chicago